Daiichi Sankyo unit accuses Pharmacosmos of patent infringement
12-02-2020
Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute
14-11-2019
AstraZeneca to launch CRISPR-based cancer research centre
11-12-2018
Roland Magnusson / Shutterstock.com
Biopharmaceutical company AstraZeneca has entered into an agreement with Japanese pharmaceutical company Daiichi Sankyo to develop and commercialise trastuzumab deruxtecan, a potential new medicine for cancer treatment.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AstraZeneca, cancer, Daiichi Sankyo, trastuzumab deruxtecan, development and commercialisation
